XOMA Royalty Business Summary

XOMA Royalty Corp (XOMA) operates as a specialized biotechnology royalty aggregator, generating revenue through the acquisition and management of economic rights—primarily potential future royalties and milestone payments—associated with partnered therapeutic candidates. Unlike traditional drug developers, XOMA provides non-dilutive, non-recourse funding to biotech companies in exchange for these rights, effectively insulating itself from the high costs and binary risks of internal R&D. The company’s portfolio is highly diversified, featuring over 120 assets across 11+ therapeutic categories, including oncology, immunology, and rare diseases, with significant revenue driven by commercial-stage products like Vabysmo. Within the competitive landscape, XOMA competes with larger-scale aggregators such as Royalty Pharma, Ligand Pharmaceuticals, and Healthcare Royalty Partners; however, it carves out a distinct niche by targeting smaller, earlier-stage royalty tranches that larger rivals typically overlook. Originally founded in 1981 by Dr. Patrick Scannon, XOMA has transitioned from its legacy as a discovery-stage biotech into a pure-play financial engine led by a team with deep institutional pedigree. Chief Executive Officer Owen Hughes, who assumed the role in early 2024, brings extensive experience from his tenure as CEO of Cullinan Oncology and 16 years on Wall Street at firms like Bain Capital and Fidelity. The leadership team was further strengthened in January 2026 with the appointment of Jeffrey Trigilio as CFO, who previously held senior finance roles at Obsidian Therapeutics and Alexion Pharmaceuticals, alongside Chief Investment Officer Brad Sitko, formerly of RTW Investments. The company is supported by a high-profile Board of Directors, including Chairman Jack Wyszomierski (former CFO of VWR International) and Matthew Perry of BVF Partners, reflecting a strong backing from sophisticated life sciences investors and institutional capital like Blue Owl Capital.